APA

Yeung D. T., Moulton D. J., Heatley S. L., Nievergall E., Dang P., Braley J., Branford S., Moore S., Mullighan C. G., Hughes T. P. & White D. L. (20150324). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. : Leukemia.

Chicago

Yeung D T, Moulton D J, Heatley S L, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan C G, Hughes T P and White D L. 20150324. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. : Leukemia.

Harvard

Yeung D. T., Moulton D. J., Heatley S. L., Nievergall E., Dang P., Braley J., Branford S., Moore S., Mullighan C. G., Hughes T. P. and White D. L. (20150324). Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. : Leukemia.

MLA

Yeung D T, Moulton D J, Heatley S L, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan C G, Hughes T P and White D L. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. : Leukemia. 20150324.